hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
复制标题
DOI：
10.3748/wjg.v20.i26.8482
复制
发表时间：
2014-07-14
影响因子：
4.3
通讯作者：
Andersson, Roland
中科院分区：
文献类型：
--
作者：
Nordh, Stina;Ansari, Daniel;Andersson, Roland
在几项研究中，高人平衡型核苷转运蛋白1（hENT1）表达显示了吉西他滨治疗胰腺癌患者的生存获益。本系统评价的目的是总结结果，并尝试评估hENT1对确定吉西他滨在胰腺癌中的预后的预测价值。从PubMed、Embase和科克伦数据库中获取相关文章。选择了评估吉西他滨治疗患者胰腺肿瘤细胞中hENT 1表达的研究。结果指标为总生存期、无病生存期（DFS）、毒性反应和缓解率。数据库检索确定了10项符合合格标准的研究，共纳入855例患者。10项研究中有9项在单变量分析中显示，hENT1高表达患者的总生存期比低表达患者的总生存期长，具有统计学意义。在报告DFS作为结局指标的7项研究中，6项hENT1高水平组的DFS在统计学上较长。仅2篇文章报告了毒性和缓解率，因此难以得出任何主要结论。这篇综述提供了证据表明hENT1是吉西他滨治疗胰腺癌患者的预测标志物。必须考虑到综述的一些局限性，大多数纳入的研究具有回顾性设计，并且没有hENT1表达的标准化评分方案。(C)2014百世登出版集团股份有限公司All rights reserved.
High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer. Relevant articles were obtained from PubMed, Embase and Cochrane databases. Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected. Outcome measures were overall survival, disease-free survival (DFS), toxicity and response rate. The database searches identified 10 studies that met the eligibility criteria, and a total of 855 patients were included. Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression. In the 7 studies that reported DFS as an outcome measure, 6 had statistically longer DFS in the high hENT1 groups. Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions. This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine. Some limitations of the review have to be taken into consideration, the majority of the included studies had a retrospective design, and there was no standardized scoring protocol for hENT1-expression. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.